University College London Hospital starts the collection of blood samples to evaluate IMMray™ PanCan-d in symptomatic patients
University College London Hospital will assess Immunovia’s IMMray™ PanCan-d in 360 patients with symptoms suggestive of early pancreatic cancerLUND, Sweden ― Immunovia today announced that Prof. Pereira and his team at the Institute for Liver and Digestive Health, University College London (UCL) have started the collection of 360 blood samples funded by London Cancer Vanguard, for a study that aims to assess IMMray PanCan-d utility in patients with abdominal symptoms attending secondary care centres such as clinics, multidisciplinary diagnostic centres (MDC), and endoscopy/gastrointestinal